

Guillaume Cartron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7496680/publications.pdf>

Version: 2024-02-01

166
papers

8,748
citations

57631

44
h-index

46693

89
g-index

171
all docs

171
docs citations

171
times ranked

9531
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc γ R3 gene. <i>Blood</i> , 2002, 99, 754-758.	0.6	1,819
2	From the bench to the bedside: ways to improve rituximab efficacy. <i>Blood</i> , 2004, 104, 2635-2642.	0.6	494
3	Rituximab-Dependent Cytotoxicity by Natural Killer Cells. <i>Cancer Research</i> , 2004, 64, 4664-4669.	0.4	395
4	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	13.9	313
5	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	13.9	264
6	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	0.6	231
7	Clinical radioimmunotherapy—the role of radiobiology. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 720-734.	12.5	191
8	Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2912-2919.	0.8	185
9	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. <i>Blood</i> , 2012, 119, 5126-5132.	0.6	175
10	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 2402-2411.	6.3	157
11	Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. <i>Blood</i> , 2014, 124, 2196-2202.	0.6	138
12	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2920-2926.	0.8	137
13	Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 104-110.	0.8	134
14	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012, 119, 3698-3704.	0.6	125
15	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	0.6	121
16	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013, 122, 1137-1143.	0.6	120
17	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. <i>Blood</i> , 2016, 128, 1081-1092.	0.6	120
18	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009, 113, 3765-3772.	0.6	116

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of rituximab and its clinical use: Thought for the best use?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 43-52.	2.0	109
20	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	0.6	104
21	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011, 96, 1128-1135.	1.7	99
22	Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies. <i>Clinical Cancer Research</i> , 2011, 17, 19-30.	3.2	86
23	Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	1.4	83
24	Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 34-42.	2.0	79
25	Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2725-2731.	0.8	77
26	EZH2 in normal hematopoiesis and hematological malignancies. <i>Oncotarget</i> , 2016, 7, 2284-2296.	0.8	77
27	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017, 129, 2616-2623.	0.6	73
28	Hybrid gadolinium oxide nanoparticles combining imaging and therapy. <i>Journal of Materials Chemistry</i> , 2009, 19, 2328.	6.7	72
29	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. <i>Haematologica</i> , 2013, 98, 1107-1114.	1.7	70
30	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. <i>Haematologica</i> , 2016, 101, 976-984.	1.7	70
31	Obinutuzumab: what is there to learn from clinical trials?. <i>Blood</i> , 2017, 130, 581-589.	0.6	70
32	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , 2021, 137, 877-887.	0.6	68
33	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. <i>Blood</i> , 2015, 126, 2646-2649.	0.6	64
34	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	2.2	64
35	Association between textural and morphological tumor indices on baseline ^{18}F -PET/CT and early metabolic response on interim ^{18}F -PET/CT in bulky malignant lymphomas. <i>Medical Physics</i> , 2017, 44, 4608-4619.	1.6	60
36	Evidence for Linkage Disequilibrium Between $\text{Fc}\gamma\text{RIIIa-V158F}$ and $\text{Fc}\gamma\text{RIIIa-H131R}$ Polymorphisms in White Patients, and for an $\text{Fc}\gamma\text{RIIIa}$ -Restricted Influence on the Response to Therapeutic Antibodies. <i>Journal of Clinical Oncology</i> , 2008, 26, 5489-5491.	0.8	58

#	ARTICLE	IF	CITATIONS
37	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012, 120, 2650-2657.	0.6	56
38	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> , 2022, 140, 839-850.	0.6	55
39	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. <i>European Journal of Cancer</i> , 2020, 136, 4-6.	1.3	53
40	Obinutuzumab in hematologic malignancies: Lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015, 41, 784-792.	3.4	52
41	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 383-389.	1.3	52
42	Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. <i>British Journal of Haematology</i> , 2020, 190, e154-e156.	1.2	52
43	CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. <i>FASEB Journal</i> , 2006, 20, 1913-1915.	0.2	49
44	Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. <i>Theranostics</i> , 2019, 9, 540-553.	4.6	49
45	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/CS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	0.6	48
46	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. <i>Autoimmunity Reviews</i> , 2018, 17, 115-124.	2.5	48
47	Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. <i>Theranostics</i> , 2018, 8, 3856-3869.	4.6	48
48	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
49	Targeting the SUMO Pathway Primes All-trans Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. <i>Cancer Research</i> , 2018, 78, 2601-2613.	0.4	45
50	CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. <i>PLoS ONE</i> , 2016, 11, e0150434.	1.1	44
51	Localized Low-Dose Radiotherapy for Follicular Lymphoma: History, Clinical Results, Mechanisms of Action, and Future Outlooks. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 975-982.	0.4	43
52	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. <i>Immunity</i> , 2021, 54, 1788-1806.e7.	6.6	43
53	Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production. <i>EBioMedicine</i> , 2016, 3, 43-53.	2.7	41
54	Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 884-884.	0.6	41

#	ARTICLE	IF	CITATIONS
55	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021, 137, 2646-2656.	0.6	39
56	Mitochondrial Complex I activity signals antioxidant response through ERK5. <i>Scientific Reports</i> , 2018, 8, 7420.	1.6	38
57	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 539-548.	2.5	38
58	Obinutuzumab. <i>Current Opinion in Oncology</i> , 2014, 26, 484-491.	1.1	34
59	PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. <i>Clinical Epigenetics</i> , 2018, 10, 121.	1.8	32
60	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 226-234.	1.7	31
61	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. <i>British Journal of Cancer</i> , 2018, 118, 1062-1073.	2.9	30
62	The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. <i>Oncotarget</i> , 2015, 6, 19228-19245.	0.8	28
63	Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. <i>Human Pathology</i> , 2017, 64, 128-136.	1.1	25
64	NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. <i>Oncolmmunology</i> , 2018, 7, e1409322.	2.1	25
65	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	0.6	25
66	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. <i>Oncolmmunology</i> , 2021, 10, 1853314.	2.1	24
67	A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease. <i>Blood</i> , 2008, 112, 234-234.	0.6	23
68	Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. <i>EBioMedicine</i> , 2015, 2, 1364-1376.	2.7	22
69	miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. <i>Haematologica</i> , 2017, 102, 746-754.	1.7	22
70	Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. <i>Oncotarget</i> , 2018, 9, 1114-1129.	0.8	22
71	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017, 56, 635-647.	1.6	21
72	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 597-605.	1.1	20

#	ARTICLE	IF	CITATIONS
73	New anti-CD20 monoclonal antibodies: which is the best?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1-2.	0.6	20
74	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e470-e479.	2.2	20
75	Development of a drugâ€ disease simulation model for rituximab in follicular nonâ€Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 561-573.	1.1	19
76	Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3627-3633.	0.4	19
77	Follicular lymphoma dynamics. <i>Advances in Immunology</i> , 2021, 150, 43-103.	1.1	19
78	Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche. <i>Blood</i> , 2021, 138, 57-70.	0.6	19
79	G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitorâ€ mediated cell death. <i>Blood Advances</i> , 2021, 5, 2325-2338.	2.5	19
80	Comparison of EBV DNA viral load in whole blood, plasma, Bâ€ cells and Bâ€ cell culture supernatant. <i>Journal of Medical Virology</i> , 2014, 86, 851-856.	2.5	18
81	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. <i>Blood</i> , 2022, 139, 2338-2346.	0.6	18
82	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 273-286.	2.0	17
83	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	0.8	17
84	Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 20.	6.9	17
85	Obinutuzumab for relapsed or refractory indolent non-Hodgkinâ€™s lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 85-93.	1.1	17
86	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4393-4393.	0.6	17
87	Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy A comparison with steady-state bone marrow and peripheral blood. <i>Experimental Hematology</i> , 2002, 30, 74-81.	0.2	16
88	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019, 33, 776-780.	3.3	16
89	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020, 4, 3217-3223.	2.5	16
90	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4196-4196.	0.6	16

#	ARTICLE	IF	CITATIONS
91	Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).. Blood, 2009, 114, 1704-1704.	0.6	16
92	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Brutonâ€™s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia, 2020, 34, 1458-1461.	3.3	15
93	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia, 2021, 35, 1597-1609.	3.3	15
94	Occupational exposure to pesticides and prognosis of diffuse large B-cell lymphoma: A cohort study.. Journal of Clinical Oncology, 2018, 36, 1564-1564.	0.8	14
95	Targeting Cellular Iron Homeostasis with Ionomycin in Diffuse Large B-cell Lymphoma. Cancer Research, 2022, 82, 998-1012.	0.4	14
96	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 2016, 7, 85573-85583.	0.8	13
97	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia, 2021, 35, 2108-2113.	3.3	13
98	Time for an individualized approach to first-line management of follicular lymphoma. Haematologica, 2022, 107, 7-18.	1.7	13
99	High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma. Experimental and Therapeutic Medicine, 2010, 1, 933-938.	0.8	12
100	Increased T-Cell Activation and Th1 Cytokine Concentrations Prior to the Diagnosis of B-Cell Lymphoma in HIV Infected Patients. Journal of Clinical Immunology, 2013, 33, 22-29.	2.0	12
101	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the Râ€™NIMP GOELAMS study. British Journal of Haematology, 2013, 162, 240-249.	1.2	12
102	DNA repair in diffuse large B-cell lymphoma: a molecular portrait. British Journal of Haematology, 2015, 169, 296-299.	1.2	12
103	The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia, 2020, 34, 1315-1328.	3.3	12
104	An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Oncotarget, 2018, 9, 19079-19099.	0.8	11
105	Adverse reactions related to brentuximab vedotin use: A real-life retrospective study. Therapie, 2019, 74, 343-346.	0.6	10
106	A fixed-duration, measurable residual diseaseâ€™guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood, 2021, 137, 1019-1023.	0.6	10
107	Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma: Results from a Phase 1b Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e443-e451.	0.2	10
108	Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. Blood, 2005, 106, 1503-1505.	0.6	9

#	ARTICLE	IF	CITATIONS
109	Inherited or acquired modifiers of iron status may dramatically affect the phenotype in dehydrated hereditary stomatocytosis. <i>European Journal of Haematology</i> , 2018, 101, 566-569.	1.1	9
110	Quantitative and Qualitative Analysis of the Human Primitive Progenitor Cell Compartment after Autologous Stem Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 359-368.	1.8	8
111	Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. <i>Experimental Hematology</i> , 2003, 31, 89-97.	0.2	8
112	Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function. <i>Vaccines</i> , 2020, 8, 727.	2.1	8
113	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 184-184.	0.6	8
114	Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study. <i>Blood</i> , 2018, 132, 999-999.	0.6	8
115	Maintenance therapy for low-grade lymphomas: has the time come?. <i>Current Opinion in Oncology</i> , 2007, 19, 425-432.	1.1	7
116	<i>FCGR3A</i> polymorphism story: a new piece of the puzzle. <i>Leukemia and Lymphoma</i> , 2009, 50, 1401-1402.	0.6	7
117	<i>Citrobacter koseri</i> Cellulitis During Anti-CD20 Monoclonal Antibody (Ofatumumab) Treatment for B-cell Chronic Lymphocytic Leukaemia. <i>Acta Dermato-Venereologica</i> , 2010, 90, 99-100.	0.6	7
118	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018, 103, e356-e359.	1.7	7
119	Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e192093.	2.8	7
120	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1495-1506.	1.1	7
121	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	1.7	7
122	Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 4158-4158.	0.6	7
123	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , 2011, 118, 270-270.	0.6	7
124	Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. <i>Leukemia and Lymphoma</i> , 2016, 57, 1149-1153.	0.6	6
125	Ruxolitinib for refractory large granular lymphocyte leukemia. <i>American Journal of Hematology</i> , 2021, 96, E368-E370.	2.0	6
126	Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients – First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. <i>Blood</i> , 2010, 116, 2878-2878.	0.6	6

#	ARTICLE	IF	CITATIONS
127	Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 2862-2862.	0.6	6
128	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199,) Tj ETQq0 0 0 rgBT /Overlock 1 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 829-829.	0.6	6
129	The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 136-136.	0.6	6
130	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2022, 61, 423-437.	1.6	5
131	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 755623.	2.2	5
132	Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak. <i>Leukemia and Lymphoma</i> , 2022, 63, 2686-2690.	0.6	5
133	Gota et al. on their article "the pharmacokinetics of Redituxâ,,ç, a biosimilar of rituximab" Cancer Chemotherapy and Pharmacology, 2016, 78, 1317-1318.	1.1	4
134	Scientific Significance of Clinically Insignificant FcÎ³RIIIa-V158F Polymorphism. <i>Clinical Cancer Research</i> , 2016, 22, 787-789.	3.2	4
135	Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1705-1709.	3.3	4
136	Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 66-66.	0.6	4
137	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4202-4202.	0.6	4
138	Firstâ€line therapy for chronic lymphocytic leukemia in patients older than 79Âyears is feasible and achieves good results: A FILO retrospective study. <i>Hematological Oncology</i> , 2017, 35, 671-678.	0.8	3
139	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. <i>Cancers</i> , 2020, 12, 2874.	1.7	3
140	BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres^{â€}. <i>British Journal of Haematology</i> , 2021, 192, e94-e98.	1.2	3
141	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase 1b Study BO21000),. <i>Blood</i> , 2011, 118, 3704-3704.	0.6	3
142	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). <i>Haematologica</i> , 2021, 106, 2834-2844.	1.7	3
143	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. <i>Blood</i> , 2020, 136, 20-21.	0.6	3
144	Biotherapies: Are they Just Like any Other Drugs?. <i>Therapie</i> , 2007, 62, 235-239.	0.6	2

#	ARTICLE	IF	CITATIONS
145	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. Blood, 2018, 132, 446-446.	0.6	2
146	Late Relapse of Localized High-Grade Non-Hodgkinâ€™s Lymphoma: Clinical and Biological Features. Blood, 2008, 112, 2603-2603.	0.6	2
147	Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR. Blood, 2021, 138, 641-641.	0.6	2
148	Monoclonal Antibodies for Lymphoma. , 2013, , 345-361.		1
149	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood, 2018, 132, 1859-1859.	0.6	1
150	First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. Blood, 2015, 126, 4170-4170.	0.6	1
151	Inherited and Acquired Modifiers of Iron Status May Dramatically Affect the Phenotypic Expression of Dehydrated Hereditary Stomatocytosis. Blood, 2016, 128, 1281-1281.	0.6	1
152	Efficacy and Safety of Alemtuzumab in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia after Autologous Stem Cell Transplantation.. Blood, 2004, 104, 2509-2509.	0.6	1
153	Coagulopathy Following Chimeric Antigen Receptor T Cell Therapy in R/R Adult B Cell Malignancies: A Single Center Experience. Blood, 2021, 138, 4839-4839.	0.6	1
154	Prognostic factors for lymphomas. , 2001, , 32-54.		0
155	In Follicular Lymphoma (FL), Î³Î±-Lymphocytes (Î³Î±T) Are Present and Expandable from Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas.. Blood, 2008, 112, 1773-1773.	0.6	0
156	Follicular lymphoma prognostic factors in the modern era: what is clinically significant?. Hematologie, 2011, 17, 189-202.	0.0	0
157	First Lymphoma Study Association workshops Deauville (France), 10th-12th October 2013 â€™ÂpartÂ2. Hematologie, 2014, 20, 68-77.	0.0	0
158	Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams -075. Blood, 2015, 126, 3920-3920.	0.6	0
159	Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma. Blood, 2015, 126, 588-588.	0.6	0
160	High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the lcll 07 Filo Trial. Blood, 2018, 132, 1858-1858.	0.6	0
161	BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma: A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 4612-4612.	0.6	0
162	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5344-5344.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Immunological Approaches. Technik Im Fokus, 2019, , 307-324.	0.2	0
164	Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. Leukemia and Lymphoma, 2021, 62, 3160-3169.	0.6	0
165	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. Blood, 2020, 136, 35-35.	0.6	0
166	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. Cancers, 2022, 14, 1761.	1.7	0